- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05181683
COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers
June 15, 2022 updated by: Regeneron Pharmaceuticals
A Phase 1, Randomized, Open-Label Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers
The primary objective of the study is to assess the safety and tolerability of co-formulated subcutaneous (SC) and intravenous (IV) casirivimab+imdevimab
The secondary objectives of the study are to:
- Explore variability in the drug concentration profiles of casirivimab and imdevimab after co-formulated subcutaneous (SC) or intravenous (IV) administration
- Characterize the immunogenicity of casirivimab and imdevimab in serum over time
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 1
Expanded Access
Available outside the clinical trial.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33186
- Regeneron study Site
-
Winter Park, Florida, United States, 32789
- Regeneron StudySite
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Is healthy, or has chronic medical condition(s) that per the opinion of the investigator is (are) stable, well-controlled, and not likely to require medical intervention through the end of study
- Does not require medication(s) for co-morbid condition, or has received stable medication(s) for co-morbid condition(s) for at least 6 months prior to screening
- Weighs between ≥60 kg and ≤100 kg at the time of screening
- Has SARS-CoV-2-negative reverse-transcriptase polymerase chain reaction (RT-PCR) from a sample collected ≤72 hours prior to randomization, using local assay and sample collection and assay standards
- Has completed a full course of COVID-19 vaccination more than 6 weeks prior to randomization
Key Exclusion Criteria:
- Has active respiratory or non-respiratory symptoms consistent with COVID-19 in the opinion of the Investigator
- Has recent SARS-CoV-2 infection that resolved within 6 weeks prior to randomization
- Prior use of casirivimab+imdevimab at any time prior to randomization
- Prior, current, or planned use during the study of any of the following treatments: COVID-19 convalescent plasma, other monoclonal antibodies against SARS-CoV-2 (eg, bamlanivimab and etesevimab, sotrovimab), intravenous immunoglobulin (any indication), or any other investigational, authorized, or approved agent intended for COVID-19 treatment or prevention (with the exception of COVID-19 vaccines)
- Treatment with another investigational drug in the last 30 days or within 5 half-lives of the investigational drug, whichever is longer, prior to screening
- Body mass index (BMI) ≥28 kg/m2
- Medically-attended acute illness, systemic antibiotics use, or hospitalization for any reason within 30 days prior to screening
- Acute exacerbation of a chronic pulmonary condition (eg, chronic obstructive pulmonary disease [COPD], asthma exacerbations) in the past 6 months prior to screening
- Uncontrolled hypertension, in the opinion of the investigator
- History of heart failure hospitalization, diagnosis of a myocardial infarction, stroke, transient ischemic attack, unstable angina, percutaneous or surgical revascularization procedure (coronary, carotid, or peripheral vascular), or intracardiac device placement (eg, pacemaker) within 12 months prior to screening
- Cancer requiring treatment currently or in the past 5 years, except for non-melanoma skin cancer or cervical/anus in-situ
- Is pregnant at screening
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Co-formulated casirivimab+imdevimab SC
Randomized 1:1
|
Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
Other Names:
|
EXPERIMENTAL: Co-formulated casirivimab+imdevimab IV
Randomized 1:1
|
Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Targeted grade ≥3 treatment-emergent adverse events (TEAEs)
Time Frame: Through end of study, approximately 16 weeks
|
Through end of study, approximately 16 weeks
|
Grade ≥3 injection-site reactions (ISRs)
Time Frame: Through end of study, approximately 16 weeks
|
Through end of study, approximately 16 weeks
|
Grade ≥2 infusion-related reactions (IRRs)
Time Frame: Through end of study, approximately 16 weeks
|
Through end of study, approximately 16 weeks
|
Grade ≥2 hypersensitivity reactions
Time Frame: Through end of study, approximately 16 weeks
|
Through end of study, approximately 16 weeks
|
Serious adverse events (SAEs)
Time Frame: Through end of study, approximately 16 weeks
|
Through end of study, approximately 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Concentrations of casirivimab and imdevimab in serum over time
Time Frame: Up to 16 weeks
|
Up to 16 weeks
|
Incidence and titer of anti-drug antibodies (ADA) to casirivimab and imdevimab
Time Frame: Up to 16 weeks
|
Up to 16 weeks
|
Incidence of neutralizing antibodies (NAb) to casirivimab and imdevimab
Time Frame: Up to 16 weeks
|
Up to 16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 7, 2022
Primary Completion (ACTUAL)
June 3, 2022
Study Completion (ACTUAL)
June 3, 2022
Study Registration Dates
First Submitted
January 4, 2022
First Submitted That Met QC Criteria
January 4, 2022
First Posted (ACTUAL)
January 6, 2022
Study Record Updates
Last Update Posted (ACTUAL)
June 21, 2022
Last Update Submitted That Met QC Criteria
June 15, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- R10933-10987-COV-2179
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD Sharing Time Frame
When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
IPD Sharing Access Criteria
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli.
Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Casirivimab+Imdevimab
-
University of UlmCompletedCOVID-19 | Critically Ill | Outcome, Fatal | Interleukin 6 | TocilizumabGermany
-
Regeneron PharmaceuticalsNo longer available
-
Regeneron PharmaceuticalsTerminated
-
Regeneron PharmaceuticalsTerminatedCOVID-19United States, Mexico, Romania
-
Regeneron PharmaceuticalsTerminatedImmunocompromisedUnited States, Mexico
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Recruiting
-
Erin McCrearyUniversity of PittsburghTerminated
-
Regeneron PharmaceuticalsCompletedHealthy ParticipantsUnited States, Moldova, Republic of, Romania
-
Regeneron PharmaceuticalsCompleted
-
Regeneron PharmaceuticalsTerminated